471 related articles for article (PubMed ID: 17502303)
1. [Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases)].
Admou B; Arji N; Seghrouchni F; Missoum H; El Fenniri L; Amghar S; El Aouad R
Ann Biol Clin (Paris); 2007; 65(3):291-7. PubMed ID: 17502303
[TBL] [Abstract][Full Text] [Related]
2. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies in systemic sclerosis.
Steen VD
Semin Arthritis Rheum; 2005 Aug; 35(1):35-42. PubMed ID: 16084222
[TBL] [Abstract][Full Text] [Related]
4. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.
Mitri GM; Lucas M; Fertig N; Steen VD; Medsger TA
Arthritis Rheum; 2003 Jan; 48(1):203-9. PubMed ID: 12528120
[TBL] [Abstract][Full Text] [Related]
5. Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA.
Mahler M; You D; Baron M; Taillefer SS; Hudson M; ; Fritzler MJ
Clin Chim Acta; 2011 Oct; 412(21-22):1937-43. PubMed ID: 21756890
[TBL] [Abstract][Full Text] [Related]
6. [Anti-nuclear antibodies (ANA) in sera of aged subjects, with special reference to two cases with high titers of anti-centromere antibody (ACA)].
Moteki S; Yoshida H; Watanabe N; Sato K; Saito M
Rinsho Byori; 1991 Mar; 39(3):273-7. PubMed ID: 2051602
[TBL] [Abstract][Full Text] [Related]
7. [Nuclear antibodies as serologic markers in progressive systemic scleroderma].
Lakomek HJ; Guldner HH; Bautz FA; Goerz G; Kind P; Mensing H; Krüskemper HL
Hautarzt; 1987 Feb; 38(2):63-9. PubMed ID: 3106261
[TBL] [Abstract][Full Text] [Related]
8. Anti-centromere antibodies in patients with systemic lupus erythematosus.
Respaldiza N; Wichmann I; Ocaña C; Garcia-Hernandez FJ; Castillo MJ; Magariño MI; Magariño R; Torres A; Sanchez-Roman J; Nuñez-Roldan A
Scand J Rheumatol; 2006; 35(4):290-4. PubMed ID: 16882593
[TBL] [Abstract][Full Text] [Related]
9. [The significance of autoantibodies coexisting with anti-centromere antibodies in sera of patients with primary biliary cirrhosis].
Moteki S; Yoshida H; Nishimaki T; Morito T
Rinsho Byori; 1990 Aug; 38(8):888-94. PubMed ID: 2232249
[TBL] [Abstract][Full Text] [Related]
10. Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients.
Rodriguez-Reyna TS; Hinojosa-Azaola A; Martinez-Reyes C; Nuñez-Alvarez CA; Torrico-Lavayen R; García-Hernández JL; Cabiedes-Contreras J
Autoimmunity; 2011 Nov; 44(7):576-84. PubMed ID: 21875377
[TBL] [Abstract][Full Text] [Related]
11. The concurrence of rheumatoid arthritis and limited systemic sclerosis: clinical and serologic characteristics of an overlap syndrome.
Zimmermann C; Steiner G; Skriner K; Hassfeld W; Petera P; Smolen JS
Arthritis Rheum; 1998 Nov; 41(11):1938-45. PubMed ID: 9811047
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody profile in systemic sclerosis.
Behmanesh F; Amin R; Khajedaluee M; Fritzler MJ
Acta Med Iran; 2010; 48(1):12-20. PubMed ID: 21137663
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of patients with both anti-U1RNP and anti-centromere antibodies.
Takada K; Suzuki K; Matsumoto M; Okada M; Nakanishi T; Horikoshi H; Higuchi T; Ohsuzu F
Scand J Rheumatol; 2008; 37(5):360-4. PubMed ID: 18686191
[TBL] [Abstract][Full Text] [Related]
14. Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.
Vázquez-Abad D; Grodzicky T; Senécal JL
Clin Immunol; 1999 Feb; 90(2):182-9. PubMed ID: 10080829
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies to HMG-17 nucleosomal protein in patients with scleroderma.
Vlachoyiannopoulos PG; Boumba VA; Tzioufas AG; Seferiadis C; Tsolas O; Moutsopoulos HM
J Autoimmun; 1994 Apr; 7(2):193-201. PubMed ID: 8037838
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
Elkayam O; Burke M; Vardinon N; Zakut V; Yitzhak RB; Paran D; Levartovsky D; Litinsky I; Caspi D
Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
[TBL] [Abstract][Full Text] [Related]
17. Immunological markers of the subsets of systemic scleroderma and its overlap.
Jabłońska S; Błaszczyk M; Jarzabek-Chorzelska M; Chorzelski T; Kołacińska-Strasz Z
Arch Immunol Ther Exp (Warsz); 1991; 39(4):381-90. PubMed ID: 1821614
[TBL] [Abstract][Full Text] [Related]
18. [Pulmonary manifestation of progressive systemic scleroderma: prognostic value of centromere antibodies and antibodies to Scl-70 nucleoprotein].
Behr J; König G; Meurer M; Krieg T
Pneumologie; 1990 Jun; 44(6):822-5. PubMed ID: 2381889
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus.
Nakano M; Ohuchi Y; Hasegawa H; Kuroda T; Ito S; Gejyo F
J Rheumatol; 2000 Jun; 27(6):1403-7. PubMed ID: 10852261
[TBL] [Abstract][Full Text] [Related]
20. Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis.
Tamby MC; Servettaz A; Guilpain P; Tamas N; Berezné A; Batteux F; Reinbolt J; Guillevin L; Weill B; Mouthon L
Clin Immunol; 2007 Apr; 123(1):82-8. PubMed ID: 17258939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
